{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:41:27Z","timestamp":1786650087808,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:p>Patients diagnosed with rheumatoid arthritis have a heightened susceptibility to infections, which may lead to higher rates of illness and death. The heightened susceptibility may arise from the illness itself, which causes changes in the body\u2019s innate cellular defense mechanisms, or from the medications used to manage the condition. The precise level of risk for infections associated with traditional disease-modifying anti-rheumatic drugs has not been fully elucidated. This review aimed To investigate the type of infections and the use of antibiotics among patients with rheumatoid arthritis. An electronic literature search was conducted using the MEDLINE database, with the indicated search keywords: infections, antibiotics, use, patients, rheumatoid, and arthritis. To identify relevant information, the search was limited to articles published between 2017 and 2024. The researchers used suitable search terms on Google Scholar to discover and examine relevant scholarly articles. The selection of articles was determined by several inclusion criteria. The research included publications that were published from 2017 to 2024. The study was organized into many sections, each including particular categories within the analysis section.we reportrd that : Within the developing age of focused synthetic treatments for RA, severe infections persist as the primary consequence of long-term treatment. In all patients with rheumatoid arthritis, it is necessary to conduct initial screenings for hepatitis B virus and tuberculosis. Additionally, it is important to administer vaccinations for specific pathogens (such as pneumococcal, herpes zoster, and influenza) before and during treatment. Aggressive therapy should be pursued to effectively manage disease activity in RA patients, while also maintaining constant vigilance for early signs of infections. Extra care should be given to senior rheumatoid arthritis (RA) patients who are over 65 years old and have other medical conditions. These people are often more susceptible to developing infections, regardless of the medication they get. The trials conducted with different antibiotics have confirmed the effectiveness of these medications in treating rheumatoid arthritis. Thus, it is plausible that the culprit responsible for rheumatoid arthritis is a microbe, namely periodontopathic bacteria.<\/jats:p>","DOI":"10.4103\/jfmpc.jfmpc_739_24","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T09:03:40Z","timestamp":1736759020000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["The type of infections and the use of antibiotics among patients with rheumatoid arthritis: A review"],"prefix":"10.4103","volume":"14","author":[{"given":"Asma D.","family":"Alshammari","sequence":"first","affiliation":[{"name":"Intensive Care Department, Maternity and Children Hospital, Hafar Albatin, Al-Qaysumah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona Matar","family":"Aldhafeeri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, University of Hafar Albatin, Hafar Albatin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal M.","family":"Aldhafeeri","sequence":"additional","affiliation":[{"name":"Medical Laboratories Department, College of Applied Medical Sciences, University of Hafar Albatin, Hafar Albatin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maram Asaad","family":"Alanzi","sequence":"additional","affiliation":[{"name":"Medical Laboratories Department, College of Applied Medical Sciences, University of Hafar Albatin, Hafar Albatin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Bandar","family":"Almutairi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, University of Hafar Albatin, Hafar Albatin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawaher Abdullah","family":"Alrasheedi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, University of Hafar Albatin, Hafar Albatin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thikra Adel","family":"Alsurur","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, University of Hafar Albatin, Hafar Albatin, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aeshah Dhahawi","family":"Alshammri","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, University of Hafar Albatin, Hafar Albatin, Al-Qaysumah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"689698","DOI":"10.3389\/fmed.2021.689698","article-title":"Etiology and risk factors for rheumatoid arthritis:A state-of-the-art review","volume":"8","author":"Rom\u00e3o","year":"2021","journal-title":"Front Med"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"e011916","DOI":"10.1136\/bmjopen-2016-011916","article-title":"Periodontitis in early and chronic rheumatoid arthritis:A prospective follow-up study in Finnish population","volume":"7","author":"\u00c4yr\u00e4v\u00e4inen","year":"2017","journal-title":"BMJ Open"},{"key":"R3-20260109","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39259","article-title":"Microbiome in inflammatory arthritis and human rheumatic diseases","volume":"68","author":"Scher","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"15613","DOI":"10.1038\/s41598-017-15802-x","article-title":"Alteration of the intestinal microbiome characterizes preclinical inflammatory arthritis in mice and its modulation attenuates established arthritis","volume":"7","author":"Rogier","year":"2017","journal-title":"Sci Rep"},{"issue":"(Suppl 1)","key":"R5-20260109","doi-asserted-by":"crossref","first-page":"129","DOI":"10.31138\/mjr.31.1.129","article-title":"Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies","volume":"31","author":"Thomas","year":"2020","journal-title":"Mediterr J Rheumatol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"101562","DOI":"10.1016\/j.berh.2020.101562","article-title":"The impact of lifestyle behaviours, physical activity and smoking on morbidity and mortality in patients with rheumatoid arthritis","volume":"34","author":"Gwinnutt","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.reumae.2018.07.010","article-title":"Efficacy and safety of combined therapy with synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis:Systematic literature review","volume":"16","author":"Al\u00e9n","year":"2020","journal-title":"Reumatol Cl\u00edn (English Edition)"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.autrev.2016.07.012","article-title":"Microbiota at the crossroads of autoimmunity","volume":"15","author":"Shamriz","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1126\/science.aad9358","article-title":"Antibiotic use and its consequences for the normal microbiome","volume":"352","author":"Blaser","year":"2016","journal-title":"Science"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"344.e1","DOI":"10.1016\/j.cmi.2014.11.016","article-title":"Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections:A culture-free analysis of gut microbiota","volume":"21","author":"Stewardson","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/1744666X.2019.1705785","article-title":"Infection risk in patients undergoing treatment for inflammatory arthritis:non-biologics versus biologics","volume":"16","author":"Chiu","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases:A US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"R15-20260109","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/acr2.11064","article-title":"Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic drugs","volume":"1","author":"Ozen","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"R16-20260109","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/annrheumdis-2017-212424","article-title":"Incidence of hip and knee replacement in patients with rheumatoid arthritis following the introduction of biological DMARDs:An interrupted time-series analysis using nationwide Danish healthcare registers","volume":"77","author":"Cordtz","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R17-20260109","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/annrheumdis-2017-212339","article-title":"Predictors of revision, prosthetic joint infection and mortality following total hip or total knee arthroplasty in patients with rheumatoid arthritis:A nationwide cohort study using Danish healthcare registers","volume":"77","author":"Cordtz","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R18-20260109","first-page":"1538","article-title":"American college of rheumatology\/American association of hip and knee surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty","author":"Goodman","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R19-20260109","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3899\/jrheum.220986","article-title":"Incidence of herpes zoster in patients with rheumatoid arthritis in the United States:A retrospective cohort study","volume":"50","author":"Singer","year":"2023","journal-title":"J Rheumatol"},{"key":"R20-20260109","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs:A systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R21-20260109","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/ard-2022-223357","article-title":"Safety of synthetic and biological DMARDs:A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Sepriano","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R22-20260109","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs:2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R23-20260109","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases:A systematic review and meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"R24-20260109","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"R25-20260109","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1136\/annrheumdis-2016-210457","article-title":"Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years:Integrated analysis of data from the global clinical trials","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R26-20260109","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1002\/art.40189","article-title":"Herpes zoster and tofacitinib:Clinical outcomes and the risk of concomitant therapy","volume":"69","author":"Winthrop","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R27-20260109","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/annrheumdis-2019-216128","article-title":"Tuberculosis in biologic users for rheumatic diseases:Results from the South African Biologics Registry (SABIO)","volume":"79","author":"Pettipher","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R28-20260109","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/rheumatology\/key023","article-title":"Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy:Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"57","author":"Rutherford","year":"2018","journal-title":"Rheumatology"},{"key":"R29-20260109","doi-asserted-by":"crossref","first-page":"27","DOI":"10.31138\/mjr.29.1.27","article-title":"Multicenter cross-sectional study of patients with rheumatoid arthritis in Greece:Results from a cohort of 2.491 patients","volume":"29","author":"Thomas","year":"2018","journal-title":"Mediterr J Rheumatol"},{"key":"R30-20260109","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3390\/jcm10030509","article-title":"The key comorbidities in patients with rheumatoid arthritis:A narrative review","volume":"10","author":"Taylor","year":"2021","journal-title":"J Clin Med"},{"key":"R31-20260109","doi-asserted-by":"crossref","first-page":"746396","DOI":"10.3389\/fphar.2021.746396","article-title":"Risk of adverse events after anti-TNF treatment for inflammatory rheumatological disease. A meta-analysis","volume":"12","author":"Li","year":"2021","journal-title":"Front Pharmacol"},{"key":"R32-20260109","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20912646","article-title":"Reactivation of hepatitis B virus infection in rheumatic diseases:Risk and management considerations","volume":"12","author":"Koutsianas","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"R33-20260109","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.2174\/1389557520999201123210025","article-title":"Recent applications of azo dyes:A paradigm shift from medicinal chemistry to biomedical sciences","volume":"21","author":"Khan","year":"2021","journal-title":"Mini Rev Med Chem"},{"key":"R34-20260109","doi-asserted-by":"crossref","first-page":"979300","DOI":"10.3389\/fphar.2022.979300","article-title":"Effect of sulfasalazine on endothelium-dependent vascular response by the activation of Nrf2 signalling pathway","volume":"13","author":"Sonmez","year":"2022","journal-title":"Front Pharmacol"},{"key":"R36-20260109","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1002\/JPER.17-0565","article-title":"Bacterial resistance to minocycline after adjunctive minocycline microspheres during periodontal maintenance:A randomized clinical trial","volume":"92","author":"Teles","year":"2021","journal-title":"J Periodontol"},{"key":"R37-20260109","first-page":"1","article-title":"Development of methotrexate and minocycline-loaded nanoparticles for the effective treatment of rheumatoid arthritis","volume":"21","author":"Janakiraman","year":"2020","journal-title":"AAPS Pharm SciTech"},{"key":"R38-20260109","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.4110\/in.2020.20.e47","article-title":"Immunotherapy of autoimmune diseases with nonantibiotic properties of tetracyclines?","volume":"20","author":"Park","year":"2020","journal-title":"Immune Netw"},{"key":"R39-20260109","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1111\/bph.13936","article-title":"The macrolide antibiotic renaissance","volume":"174","author":"Dinos","year":"2017","journal-title":"Br J Pharmacol"},{"key":"R40-20260109","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/1756-185X.13248","article-title":"Long-term efficacy and safety of add-on tacrolimus for persistent, active rheumatoid arthritis despite treatment with methotrexate and tumor necrosis factor inhibitors","volume":"21","author":"Naniwa","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"R41-20260109","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S2213-2600(23)00412-5","article-title":"Clarithromycin for early anti-inflammatory responses in community-acquired pneumonia in Greece (ACCESS):A randomised, double-blind, placebo-controlled trial","volume":"12","author":"Giamarellos-Bourboulis","year":"2024","journal-title":"Lancet Respir Med"},{"key":"R42-20260109","first-page":"97","article-title":"Current macrolide antibiotics and their mechanisms of action","volume":"2019","author":"Lohsen","journal-title":"Antibiotic drug resistance"},{"key":"R43-20260109","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3390\/biomedicines11020371","article-title":"DNA gyrase as a target for quinolones","volume":"11","author":"Spencer","year":"2023","journal-title":"Biomedicines"},{"key":"R44-20260109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/25785826.2023.2212808","article-title":"Macrophage activation syndrome triggered by methotrexate-related lymphoproliferative disease in a patient with rheumatoid arthritis","volume":"46","author":"Kato","year":"2023","journal-title":"Immunol Med"},{"key":"R45-20260109","first-page":"e15973","article-title":"Hepatotoxicity secondary to levofloxacin use","volume":"13","author":"Panahi","year":"2021","journal-title":"Cureus"}],"container-title":["Journal of Family Medicine and Primary Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_739_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:56Z","timestamp":1786647716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jfmpc.jfmpc_739_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_739_24","relation":{},"ISSN":["2249-4863","2278-7135"],"issn-type":[{"value":"2249-4863","type":"print"},{"value":"2278-7135","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-05-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}